CAPTRUST Financial Advisors’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-21
Closed -$5K 2383
2022
Q2
$5K Buy
21
+2
+11% +$670 ﹤0.01% 4066
2022
Q1
$10K Sell
19
-10
-34% -$6.04K ﹤0.01% 3791
2021
Q4
$19K Buy
29
+7
+32% +$5.35K ﹤0.01% 3301
2021
Q3
$18K Sell
22
-6
-21% -$6.09K ﹤0.01% 3219
2021
Q2
$36K Sell
28
-32
-53% -$36.1K ﹤0.01% 2715
2021
Q1
$65K Sell
60
-29
-33% -$38.3K ﹤0.01% 2249
2020
Q4
$127K Buy
89
+5
+6% +$5.33K ﹤0.01% 1392
2020
Q3
$60K Buy
84
+3
+4% +$2.18K ﹤0.01% 1563
2020
Q2
$54K Buy
+81
New +$46.8K ﹤0.01% 1595

Other funds holding CDLX

CAPTRUST Financial Advisors's CDLX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Cardlytics (CDLX) in Q3 2022, closing a stake of 21 shares — an estimated $5K sold.

CAPTRUST Financial Advisors first reported a position in CDLX in Q2 2020 and held it in 9 quarters. The position peaked at $127K in Q4 2020. 132 funds tracked by Wall St. Rank hold CDLX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Cardlytics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 21 Cardlytics shares in Q3 2022, an estimated $5K.
  • CAPTRUST Financial Advisors first reported a position in Cardlytics in Q2 2020 and held it in 9 quarters.
  • CAPTRUST Financial Advisors's Cardlytics position peaked at $127K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Cardlytics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.